Cat. No. | Product name | CAS No. |
DC7011 |
D4476 (D-4476)
Featured
D4476, a cell-permeant inhibitor of CK1δ (IC90 <10 uM), suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a, D4476 originally identified as inhibitors of activin receptor-like kinase ALK5. |
301836-43-1 |
DC9589 |
D609
Featured
D609 is a selective competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor (Ki = 6.4 μM); antiviral and antitumor agent. |
83373-60-8 |
DC7393 |
D-64131
Featured
D-64131 is a novel inhibitor of Tubulin polymerization that competitively binds with [(3)H]colchicine to αβ-Tubulin. |
74588-78-6 |
DC9259 |
DAA1106
Featured
DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptors, in mitochondrial fractions of the rat brain. |
220551-92-8 |
DC8913 |
Dabigatran etexilate mesylate
Featured
Dabigatran etexilate mesylate (BIBR 1048MS) is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM. |
872728-81-9 |
DC5149 |
Dabrafenib
Featured
Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively. Phase 3. |
1195765-45-7 |
DC4103 |
Dabrafenib Mesylate
Featured
Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. |
1195768-06-9 |
DC7182 |
Dacinostat (NVP-LAQ824, LAQ824)
Featured
Dacinostat (NVP-LAQ824, LAQ824) is a highly potent HDAC inhibitor with IC50 of 32 nM. |
404951-53-7 |
DC7394 |
Daclatasvir dihydrochloride (BMS-790052)
Featured
Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. |
1009119-65-6 |
DC4197 |
Actinomycin D
Featured
Dactinomycin (also known generically as Actinomycin D ) is the most significant member of actinomycines, which are a class of polypeptide antibiotics isolated from soil bacteria of the genus Streptomyces. |
50-76-0 |
DC20353 |
Dafadine A
Featured
Dafadine A is the first reported small-molecule DAF-9 cytochrome P450 inhibitor that robustly induces dauer formation in in the nematode Caenorhabditis elegans. |
1065506-69-5 |
DC23077 |
Daidzin
Featured
Daidzin is a potent, selective aldehyde dehydrogenase 2 (ALDH2,IC50 = 80 nM) inhibitor, which has antiallergic anti-oxidant, anti-carcinogenic, antithrombotic,and anti-atherosclerotic activities |
552-66-9 |
DCAPI1493 |
Dalbavacin
Featured
Dalbavancin, a semisynthetic lipoglycopeptide being developed for the treatment of skin and skin structure infections (SSSIs), has a half-life of 5 to 7 days in humans and offers promise for a convenient weekly dosing regimen. |
171500-79-1 |
DC3163 |
Dalcetrapib (JTT-705)
Featured
Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM. |
211513-37-0 |
DC21881 |
Danicamtiv (MYK-491)
Featured
Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency. |
1970972-74-7 |
DC11082 |
Danicopan (ACH-4471)
Featured
Danicopan (ACH-4471, ACH-0144471) is a highly potent, orally active Factor D inhibitor with Kd of 0.54 nM, inhibits the proteolytic activity of purified Factor D against substrate Factor B in complex with C3b, blocking production of Bb fragment IC50 of 15 nM. |
1903768-17-1 |
DC9689 |
Danirixin (GSK1325756)
Featured
Danirixin(GSK1325756) is a selective CXCR2 antagonist. |
954126-98-8 |
DC8238 |
Danoprevir
Featured
Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. |
850876-88-9 |
DC4125 |
PHA-739358 (danusertib)
Featured
Danusertib (PHA-739358) is an Aurora inhibitor for Aurora A/B/C, Bcr-Abl, c-RET and FGFR with IC50 of 13 nM/79 nM/61 nM, 25 nM, 31 nM and 47 nM, respectively. |
827318-97-8 |
DC6904 |
DAPAGLIFLOZIN
Featured
Dapagliflozin, also known as BMS-512148, is a drug used to treat type 2 diabetes approved in 2012 by FDA. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. In clinical trials, dapagliflozin lowered HbA1c by 0.6 versus placebo percentage points when added to metformin. |
461432-26-8 |
DC20170 |
Dapagliflozin propanediol monohydrate
Featured
Dapagliflozin propanediol belongs to the class of orally administered antidiabetic agents designated as sodiumglucose cotransporter 2 (SGLT2) inhibitors. |
960404-48-2 |
DC20941 |
DAPH-1
Featured
DAPH-1 (CGP 52411) is a small molecule that directly inhibits prion protein Sup35 prionogenesis with IC50 of 0.58 uM, inhibits and reverses the formation of Aβ42 fibers and reduces their toxicity to neurons in culture. |
145915-58-8 |